Understanding Richter Transformation: What CLL Patients Should Know image

Understanding Richter Transformation: What CLL Patients Should Know

Can't make it to the event?
We send a recording to all registered participants of the event!
Nov 30, 2026
12:00PM - 01:00PM EST
Online Event
Overview

Richter transformation is a rare complication of chronic lymphocytic leukemia (CLL) that can bring new questions and concerns for patients and their loved ones. Join Dana-Farber Cancer Institute experts Dr. Erin Parry and Dr. Nathalie Javidi-Sharifi for an in-depth discussion about Richter transformation, how it is diagnosed, available treatment approaches, and what patients should know

 

Agenda
12:00 PM
Introduction
Hannah Loosle

Hannah introduces the agenda of the event and our featured speakers Erin Parry, MD, PhD and Nathalie Javidi-Sharifi, MD, PhD

12:05 PM
Presentation
Erin Parry, MD, PhD and Nathalie Javidi-Sharifi, MD, PhD

Our guest speakers talk about richter transformation in CLL patients

12:35 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators
Healthtree contact Hannah Loosle

Hannah Loosle

Hannah joined HealthTree Foundation as the Lymphoma Education Manager in 2024. She is a Certified Health Education Specialist and is passionate about helping patients feel empowered through education and connection. Before joining HealthTree, Hannah worked in healthcare policy helping patients advocate for better care, research, and funding.
Healthtree contact Erin Parry, MD, PhD

Erin Parry, MD, PhD

Dr. Parry attended Johns Hopkins University School of Medicine where she earned an MD and a PhD. Upon graduation from medical school, Dr. Parry completed residency training in internal medicine at the Johns Hopkins Hospital followed by medical oncology fellowship at Dana-Farber/Partners CancerCare. During her fellowship, Dr. Parry conducted post-doctoral research in the laboratory of Dr. Catherine Wu on Richter transformation of chronic lymphocytic leukemia (CLL). Dr. Parry is currently an Assistant Professor of Medicine at Harvard Medical School and a Physician at Dana-Farber Cancer Institute in the Lymphoma Program and the Center for Chronic Lymphocytic Lymphoma. She runs a laboratory focused on the transformation of indolent B cell malignancies to aggressive lymphoma and mechanisms of immune evasion in CLL and B cell  lymphoma.
Healthtree contact Nathalie Javidi-Sharifi, MD, PhD

Nathalie Javidi-Sharifi, MD, PhD

Dr. Javidi-Sharifi received her undergraduate degree in Biochemistry from the Technical University of Munich in Germany and her MD/PhD in Cancer Biology from Oregon Health & Science University. She completed residency training in Internal Medicine at Oregon Health & Science University and fellowship training in Hematology/Oncology at Dana-Farber Cancer Institute/Mass General Brigham. Upon completing fellowship, she joined the faculty at Dana-Farber Cancer Institute. She is an attending physician in the Lymphoma Division and an Instructor in Medicine at Harvard Medical School. Her clinical and research interests focus on chronic lymphocytic leukemia, small lymphocytic lymphoma, Richter transformation, and related lymphoid malignancies.